Hervolution pitch at Novo BII demo-day by Peter J. Holst
Hervolution treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where Hervolution is presented by Associate Professor Peter Johannes Holst.
Steven Glazer joins Hervolution as Medical Advisor
Steven Glazer has many years of international experience in healthcare and biotechnology. He has held a number of senior positions within pharmaceutical and bioengineering companies in Europe and the US, including Novo Nordisk, Zealand Pharma, BioInvent International and Hansa Medical, and has gained deep knowledge of pharmaceutical development involving medical and regulatory planning. Steven’s current assignments […]
Hervolution presentation by Peter J. Holst
Hervolution treats cancer by target tumor virus within the human genome. In this video you can learn more about the company, where Hervolution is presented by Associate Professor Peter Johannes Holst.
Hervolution receives investment from Novo Nordisk Foundation
Hervolution is one of the three companies to join the BII Creation House program run by Novo Nordisk Foundation. After a successful Business Acceleration Academy, Hervolution was recommended for the program by an external committee and approved by the BII Board of Directors. In the coming 18 months, Inprother will be part of BioInnovation Institute […]
